| 26 0.96 (3.83%) | 10-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 32.63  |
1-year : | 38.11 |
| Resists | First : | 27.94 |
Second : | 32.63 |
| Pivot price | 24.83 |
|||
| Supports | First : | 24.65 |
Second : | 22.62 |
| MAs | MA(5) : | 26.23 |
MA(20) : | 24.61 |
| MA(100) : | 21.34 |
MA(250) : | 19.73 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 67.7 |
D(3) : | 78.9 |
| RSI | RSI(14): 56.8 |
|||
| 52-week | High : | 27.94 | Low : | 10.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CBLL ] has closed below upper band by 26.3%. Bollinger Bands are 41.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 26.51 - 26.62 | 26.62 - 26.71 |
| Low: | 24.34 - 24.47 | 24.47 - 24.57 |
| Close: | 25.78 - 25.99 | 25.99 - 26.17 |
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Wed, 14 Oct 2026
Is CeriBell’s (CBLL) Expanded EEG Software Deepening Its Moat in Critical Care Monitoring? - Yahoo Finance
Tue, 13 Oct 2026
CeriBell (CBLL) After FDA Clearance Looks Pricey Despite Stronger Adoption Hopes - Yahoo Finance
Fri, 02 Oct 2026
Option exercises accompany a 4,887-share sale at $24.38 by Ceribell (CBLL) CTO Raymond Woo. - Stock Titan
Thu, 01 Oct 2026
Ceribell Inc (CBLL-Q) Stock Price and News - The Globe and Mail
Thu, 01 Oct 2026
CeriBell: FDA Clearances And Delirium Expansion Could Create A New Growth Driver - Seeking Alpha
Wed, 30 Sep 2026
Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 38 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 11.8 (%) |
| Held by Institutions | 89.6 (%) |
| Shares Short | 2,020 (K) |
| Shares Short P.Month | 1,910 (K) |
| EPS | -1.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.35 |
| Profit Margin | -64.8 % |
| Operating Margin | -71.2 % |
| Return on Assets (ttm) | -23.4 % |
| Return on Equity (ttm) | -44 % |
| Qtrly Rev. Growth | 32.5 % |
| Gross Profit (p.s.) | 2.36 |
| Sales Per Share | 2.65 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -14.78 |
| PEG Ratio | 0 |
| Price to Book value | 7.73 |
| Price to Sales | 9.78 |
| Price to Cash Flow | -18.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|